Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Open access
Sanmamed, Miguel F., Carranza-Rua, Omar, Alfaro, Carlos, Oñate, Carmen, Martín-Algarra, Salvador, Perez, Guiomar, Landazuri, Sara F., Gonzalez, Álvaro, Gross, Stefanie, Rodriguez, Inmaculada, Muñoz-Calleja, Cecilia, Rodríguez-Ruiz, María, Sangro, Bruno, López-Picazo, José M., Rizzo, Manglio, Mazzolini, Guillermo, Pascual, Juan I., Andueza, Maria Pilar, Perez-Gracia, Jose Luis, Melero, Ignacio·2014·Clinical Cancer Research

Abstract

Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. We correlated IL8 serum levels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non–small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance. Clin Cancer Res; 20(22); 5697–707. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-3203

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 256

Metadata

Authors
Sanmamed, M. F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín-Algarra, S., Perez, G., Landazuri, S. F., Gonzalez, Á., Gross, S., Rodriguez, I., Muñoz-Calleja, C., Rodríguez-Ruiz, M., Sangro, B., López-Picazo, J. M., Rizzo, M., Mazzolini, G., Pascual, J. I., Andueza, M. P., Perez-Gracia, J. L., & Melero, I.
Venue
Clinical Cancer Research
Published
2014-11-13
Volume
20
Issue
22
Pages
5697-5707
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2143172913
Cited by
256
References
50
FWCI
6.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-3203
The paper
Sanmamed, M. F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín-Algarra, S., Perez, G., Landazuri, S. F., Gonzalez, Á., Gross, S., Rodriguez, I., Muñoz-Calleja, C., Rodríguez-Ruiz, M., Sangro, B., López-Picazo, J. M., Rizzo, M., Mazzolini, G., Pascual, J. I., Andueza, M. P., Perez-Gracia, J. L., & Melero, I. (2014). Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-3203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.